Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.
Christopher Ryan Heery
No relevant relationships to disclose
Ravi A. Madan
No relevant relationships to disclose
Marijo Bilusic
No relevant relationships to disclose
Joseph W. Kim
No relevant relationships to disclose
Nishith K. Singh
No relevant relationships to disclose
Myrna Rauckhorst
No relevant relationships to disclose
Clara Chen
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose
Walter Michael Stadler
No relevant relationships to disclose
Robert S. DiPaola
No relevant relationships to disclose
Mark N. Stein
No relevant relationships to disclose
James W. Hodge
Research Funding - Bavarian Nordic
Jeffrey Schlom
Research Funding - Bavarian Nordic
James L. Gulley
Research Funding - Bavarian Nordic